Patients who participated in the FUNCTION Study (Protocol WA19926) will be enrolled in this study. The investigators want to learn how long it takes Early Rheumatoid Arthritis patients who were treated with Tocilizumab to require treatment with another biologic medication.
Study Type
OBSERVATIONAL
Rate of Biologic Treatment
To describe the rate of requiring biologic treatment over 2 years following completion of the FUNCTION study
Time frame: 2 years
Treatment after completion of FUNCTION study
To determine the type of RA treatment regimen used by the treating physician upon completion of the FUNCTION study
Time frame: Baseline
Rate of requiring treatment intensification
To determine the rate of requiring treatment intensification with a traditional DMARD(s) completion of the FUNCTION study. The durability of response after completion of the FUNCTION study. The clinical measures of disease progression over 2 years after completion of the FUNCTION study. The clinical measures of disease progression over 2 years after completion of the FUNCTION study.
Time frame: 2 years
Change in functional status
The change in patient-reported functional status over 2 years after tocilizumab withdrawal or maintaining Mtx or changing DMARD(s)
Time frame: 2 years
Work productivity
To determine work productivity over 2 years after completion of the FUNCTION study
Time frame: 2 years
Healthcare Utilization
To determine health-care utilization over 2 years after completion of the FUNCTION study
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.